Post by Chang Sha on Aug 28, 2010 9:29:32 GMT -5
Research and Markets: Forecast Insight: Hepatitis B - Baraclude and Viread Set to Thrive
08.26.10, 05:00 AM EDT
BusinessWire - Research and Markets has announced the addition of the "Forecast Insight: Hepatitis B - Baraclude and Viread set to thrive in the face of limited competition" report to their offering.
In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009. Datamonitor expects the market to grow to $1.2 billion by 2014. However, from 2015 to 2019, sales across the seven major markets will decline due to patent expiries of key drugs such as Baraclude and Viread, and reach approximately $893m by 2019.
Scope
Analysis of the current hepatitis B market dynamics across the US, 5EU, Japan and Turkey, with a snapshot of the Rest of World countries Thorough assessment of key marketed products for hepatitis B therapy Detailed ten-year sales forecasts for marketed hepatitis B drugs in each of the seven major markets and Turkey Review of opinions of key hepatitis B opinion leaders on future market developments
Highlights of this title
In 2009, small molecule antivirals dominated the hepatitis B market with sales of $954m. In comparison, sales of interferon products were low, accounting for only 3% of total hepatitis B sales in 2009. This low market share can be attributed to the high cost of interferon products, their restricted use and inconvenient mode of administration. Market growth until 2014 will be driven by the strong uptake of newer hepatitis B antivirals such as Bristol-Myers Squibb's Baraclude (entecavir) and Gilead's Viread (tenofovir). Older products such as Gilead's Hepsera (adefovir) and GlaxoSmithKline's Zeffix (lamivudine) will be used less frequently owing to the increased risk of resistance. In 2009, Baraclude was the best selling brand in terms of value in Turkey; however Zeffix dominated in terms of volume. The popularity of Zeffix can be explained by the stringent reimbursement policy in Turkey, which restricts the use of more expensive drugs such as the pegylated interferons, Baraclude and Viread to specific populations.
Key reasons to purchase this title
Understand the changing market dynamics of hepatitis B drugs and success factors for leading brands. Assess the impact of events such as patent expiries on the overall hepatitis B market. Obtain full, country, class and product-specific forecasts of currently marketed drugs from 2009 to 2019 for all seven major markets and Turkey.
source: www.forbes.com/feeds/businesswire/2010/08/26/businesswire144405332.html
Small molecule antivirals products
- Bristol-Myers Squibb's Baraclude (entecavir)
- Gilead's Viread (tenofovir)
Interferon products
Older products
- Gilead's Hepsera (adefovir)
- GlaxoSmithKline's Zeffix (lamivudine)
08.26.10, 05:00 AM EDT
BusinessWire - Research and Markets has announced the addition of the "Forecast Insight: Hepatitis B - Baraclude and Viread set to thrive in the face of limited competition" report to their offering.
In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009. Datamonitor expects the market to grow to $1.2 billion by 2014. However, from 2015 to 2019, sales across the seven major markets will decline due to patent expiries of key drugs such as Baraclude and Viread, and reach approximately $893m by 2019.
Scope
Analysis of the current hepatitis B market dynamics across the US, 5EU, Japan and Turkey, with a snapshot of the Rest of World countries Thorough assessment of key marketed products for hepatitis B therapy Detailed ten-year sales forecasts for marketed hepatitis B drugs in each of the seven major markets and Turkey Review of opinions of key hepatitis B opinion leaders on future market developments
Highlights of this title
In 2009, small molecule antivirals dominated the hepatitis B market with sales of $954m. In comparison, sales of interferon products were low, accounting for only 3% of total hepatitis B sales in 2009. This low market share can be attributed to the high cost of interferon products, their restricted use and inconvenient mode of administration. Market growth until 2014 will be driven by the strong uptake of newer hepatitis B antivirals such as Bristol-Myers Squibb's Baraclude (entecavir) and Gilead's Viread (tenofovir). Older products such as Gilead's Hepsera (adefovir) and GlaxoSmithKline's Zeffix (lamivudine) will be used less frequently owing to the increased risk of resistance. In 2009, Baraclude was the best selling brand in terms of value in Turkey; however Zeffix dominated in terms of volume. The popularity of Zeffix can be explained by the stringent reimbursement policy in Turkey, which restricts the use of more expensive drugs such as the pegylated interferons, Baraclude and Viread to specific populations.
Key reasons to purchase this title
Understand the changing market dynamics of hepatitis B drugs and success factors for leading brands. Assess the impact of events such as patent expiries on the overall hepatitis B market. Obtain full, country, class and product-specific forecasts of currently marketed drugs from 2009 to 2019 for all seven major markets and Turkey.
source: www.forbes.com/feeds/businesswire/2010/08/26/businesswire144405332.html
Small molecule antivirals products
- Bristol-Myers Squibb's Baraclude (entecavir)
- Gilead's Viread (tenofovir)
Interferon products
Older products
- Gilead's Hepsera (adefovir)
- GlaxoSmithKline's Zeffix (lamivudine)